ARTL (Artelo Biosciences) Pre-Tax Income: $-13.47 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ARTL Artelo Biosciences Inc ARTL
31 GF Score
Price $0.77
! 2 Warning Signs
View Full Analysis

What is Artelo Biosciences Pre-Tax Income?

Artelo Biosciences ARTL +2.52% 31 Pre-Tax Income is $-13.47 Mil as of Mar. 2026. GuruFocus rates ARTL with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Pretax income is the income that a company earns before paying income taxes. Artelo Biosciences's pretax income for the three months ended in Mar. 2026 was $-2.96 Mil. Its pretax income for the trailing twelve months (TTM) ended in Mar. 2026 was $-13.47 Mil. Artelo Biosciences's pretax margin was %.


Artelo Biosciences  (NAS:ARTL) Pre-Tax Income Explanation

Artelo Biosciences's Pretax Margin for the quarter that ended in Mar. 2026 is calculated as

Pretax Margin=Pretax Income/Revenue
=-2.958/0
=%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Artelo Biosciences Pre-Tax Income Related Terms


Artelo Biosciences Pre-Tax Income Historical Data

* Premium members only.

The historical data trend for Artelo Biosciences's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Artelo Biosciences Pre-Tax Income Chart

Artelo Biosciences Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23 Dec24 Dec25
Pre-Tax Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.44 -10.08 -9.29 -9.83 -12.88

Artelo Biosciences Quarterly Data
May21 Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Pre-Tax Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.37 -3.22 -3.12 -4.17 -2.96

ARTL vs ADTX, GOVX, HCWB: Pre-Tax Income Comparison

For the Biotechnology subindustry, Artelo Biosciences's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Artelo Biosciences Pre-Tax Income vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Artelo Biosciences's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Artelo Biosciences's Pre-Tax Income falls into.


ARTL
31GF Score
Artelo Biosciences Inc ARTL
Pre-Tax Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Artelo Biosciences Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Artelo Biosciences's Pretax Income for the fiscal year that ended in Dec. 2025 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-11.404+-1.198+-0.277+0+0
=-12.88

Artelo Biosciences's Pretax Income for the quarter that ended in Mar. 2026 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-2.689+-0.146+-0.124+0.001+0
=-2.96

Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.47 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pre-Tax Income →
What does a Pre-Tax Income of $-13.47 Mil mean?
Artelo Biosciences (ARTL) has a Pre-Tax Income of $-13.47 Mil as of Mar. 2026. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Artelo Biosciences and its competitors.
Is Artelo Biosciences' Pre-Tax Income too high?
Artelo Biosciences' current Pre-Tax Income is $-13.47 Mil. Overall, Artelo Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Artelo Biosciences' Pre-Tax Income compare to ADTX and GOVX?
Artelo Biosciences' Pre-Tax Income of $-13.47 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Biotechnology company?
A good Pre-Tax Income depends on the Biotechnology industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Artelo Biosciences and its competitors. Artelo Biosciences's current Pre-Tax Income is $-13.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artelo Biosciences stock overvalued right now?
Artelo Biosciences (ARTL) has a current Pre-Tax Income of $-13.47 Mil. The current Pre-Tax Income is $-13.47 Mil. Artelo Biosciences' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For Artelo Biosciences (ARTL), the current Pre-Tax Income is $-13.47 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Artelo Biosciences Business Description

Address 505 Lomas Santa Fe, Suite 160, Solana Beach, CA, USA, 92075
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
31GF Score

Get the complete analysis for ARTL

Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.77
Price